Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial

Documenti analoghi

• Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
  di: Paul Richardson, et al.
  Pubblicazione: (2025)
• Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
  di: Sijia Yan, et al.
  Pubblicazione: (2025)
• Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone ( DRd ) Versus Bortezomib, Lenalidomide, and Dexamethasone ( VRd ) Among Transplant‐Ineligible Patients With Multiple Myeloma
  di: Doris K. Hansen, et al.
  Pubblicazione: (2024)
• Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience
  di: Oscar C. Y. Yang, et al.
  Pubblicazione: (2025)
• Characterization and Management of Cytokine Release Syndrome From the MonumenTAL ‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
  di: Niels W. C. J. van de Donk, et al.
  Pubblicazione: (2025)